Abcam held their AGM on the 22nd October at their offices in Cambridge – about half a dozen ordinary shareholders attended, much the same as last year. Glad to see they seem to have taken notice of my complaint last year about the early start time and moved it to 11.00 am – you see it does pay to moan sometimes. Abcam primarily sells antibodies via the internet to research scientists worldwide. They are one of the more successful AIM companies, with compound average sales growth of 32% per annum over the last 5 years and growth in earnings per share of 45% per annum. Shareholders who bought their shares a few years ago are no doubt very happy. Last year the pace of growth slowed somewhat, probably due to
...Not a member? Join today
Joining ShareSoc helps to empower our collective voice in representing investors, but we also offer exclusive benefits:
Member events & Masterclasses
Regular newsletter
Member only on-line Forums / Q&As
Company data and Voting Guidance
Educational resources
Get involved in our activities
Already a member?
Log in to your account to access this content and all of your other ShareSoc membership benefits.